107 related articles for article (PubMed ID: 24373724)
21. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
[TBL] [Abstract][Full Text] [Related]
22. Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Hwang SH; Tsai HJ; Liu JY; Morisseau C; Hammock BD
J Med Chem; 2007 Aug; 50(16):3825-40. PubMed ID: 17616115
[TBL] [Abstract][Full Text] [Related]
23. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
[TBL] [Abstract][Full Text] [Related]
24. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
Kim IH; Tsai HJ; Nishi K; Kasagami T; Morisseau C; Hammock BD
J Med Chem; 2007 Oct; 50(21):5217-26. PubMed ID: 17894481
[TBL] [Abstract][Full Text] [Related]
25. Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales.
Kitamura S; Morisseau C; Harris TR; Inceoglu B; Hammock BD
PLoS One; 2017; 12(5):e0176571. PubMed ID: 28472063
[TBL] [Abstract][Full Text] [Related]
26. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD
J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969
[TBL] [Abstract][Full Text] [Related]
27. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition.
Davis BB; Morisseau C; Newman JW; Pedersen TL; Hammock BD; Weiss RH
J Pharmacol Exp Ther; 2006 Feb; 316(2):815-21. PubMed ID: 16221742
[TBL] [Abstract][Full Text] [Related]
28. Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
Du F; Sun W; Morisseau C; Hammock BD; Bao X; Liu Q; Wang C; Zhang T; Yang H; Zhou J; Xiao W; Liu Z; Chen G
Eur J Med Chem; 2021 Nov; 223():113678. PubMed ID: 34218083
[TBL] [Abstract][Full Text] [Related]
29. Discovery of phthalimide derivatives as novel inhibitors of a soluble epoxide hydrolase.
Mahlooji I; Shokri M; Manoochehri R; Mahboubi-Rabbani M; Rezaee E; Tabatabai SA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000052. PubMed ID: 32484272
[TBL] [Abstract][Full Text] [Related]
30. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
Codony S; Pujol E; Pizarro J; Feixas F; Valverde E; Loza MI; Brea JM; Saez E; Oyarzabal J; Pineda-Lucena A; Pérez B; Pérez C; Rodríguez-Franco MI; Leiva R; Osuna S; Morisseau C; Hammock BD; Vázquez-Carrera M; Vázquez S
J Med Chem; 2020 Sep; 63(17):9237-9257. PubMed ID: 32787085
[No Abstract] [Full Text] [Related]
31. Potent urea and carbamate inhibitors of soluble epoxide hydrolases.
Morisseau C; Goodrow MH; Dowdy D; Zheng J; Greene JF; Sanborn JR; Hammock BD
Proc Natl Acad Sci U S A; 1999 Aug; 96(16):8849-54. PubMed ID: 10430859
[TBL] [Abstract][Full Text] [Related]
32. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea.
Watanabe T; Morisseau C; Newman JW; Hammock BD
Drug Metab Dispos; 2003 Jul; 31(7):846-53. PubMed ID: 12814960
[TBL] [Abstract][Full Text] [Related]
33. Discovery of benzamide derivatives containing urea moiety as soluble epoxide hydrolase inhibitors.
Tian Y; Li S; Dong K; Su X; Fu S; Lv X; Duan M; Yang T; Han Y; Hu G; Liu J; Sun Y; Yue H; Sun Y; Zhang H; Du Z; Miao Z; Tong M; Liu Y; Qin M; Gong P; Hou Y; Gao Z; Zhao Y
Bioorg Chem; 2022 Oct; 127():105898. PubMed ID: 35792317
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.
Pecic S; Deng SX; Morisseau C; Hammock BD; Landry DW
Bioorg Med Chem Lett; 2012 Jan; 22(1):601-5. PubMed ID: 22079754
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
[TBL] [Abstract][Full Text] [Related]
36. Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility.
Burmistrov V; Morisseau C; D'yachenko V; Karlov D; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2020 Feb; 30(3):126908. PubMed ID: 31870649
[TBL] [Abstract][Full Text] [Related]
37. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
Shen HC; Ding FX; Deng Q; Xu S; Tong X; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
Bioorg Med Chem Lett; 2009 Oct; 19(19):5716-21. PubMed ID: 19700315
[TBL] [Abstract][Full Text] [Related]
38. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.
Hwang SH; Morisseau C; Do Z; Hammock BD
Bioorg Med Chem Lett; 2006 Nov; 16(22):5773-7. PubMed ID: 16949285
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
[TBL] [Abstract][Full Text] [Related]
40. Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.
Burmistrov V; Morisseau C; Karlov D; Pitushkin D; Vernigora A; Rasskazova E; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2020 Sep; 30(18):127430. PubMed ID: 32736212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
